Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LTG-001

Other · developed by Latigo Biotherapeutics

Phase 2 Most advanced trial
LTGO Developer
4 Registered trials

What is LTG-001?

LTG-001 is an investigational drug studied in Healthy, Acute Pain, Postoperative, Acute Pain.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Latigo Biotherapeutics (LTGO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07102459 Phase 2 Acute Pain Completed LTGO
NCT06774625 Phase 2 Acute Pain, Postoperative Completed LTGO
NCT07341152 Phase 1 Pain Management Completed LTGO
NCT06049095 Phase 1 Healthy Active not recruiting LTGO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HealthyAcute PainAcute Pain, PostoperativePain ManagementPostoperative Pain Control

More from Latigo Biotherapeutics

Follow LTGO, the company behind LTG-001

See LTGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LTGO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.